Coenzyme Q10 in the Treatment of Mitochondrial Disease

AUTOR(ES)

Neergheen, Viruna

FONTE

J. inborn errors metab. screen.

DATA DE PUBLICAÇÃO

16/05/2019

RESUMO

Abstract Currently, there is a paucity of available treatment strategies for oxidative phosphorylation disorders. Coenzyme Q10 (CoQ10) and related synthetic quinones are the only agents to date that have proven to be beneficial in the treatment of these heterogeneous disorders. The therapeutic efficacy of CoQ10 is not restricted to patients with an underlying CoQ10 deficiency and is thought to result from its ability to restore electron flow in the mitochondrial respiratory chain (MRC) as well as to increase the cellular antioxidant capacity. At present, however, there is no consensus on the appropriate dosage or therapeutic plasma level of CoQ10, and this information will be required before CoQ10 can be utilized effectively in the treatment of mitochondrial disease. The following review will outline our current knowledge on the use of CoQ10 in the treatment of MRC disorders and primary CoQ10 deficiencies.

Documentos Relacionados

• Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases
• Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
• Deficiency of Coenzyme Q10 in Gingival Tissue from Patients with Periodontal Disease
• Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease
• Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes with recurrent abdominal symptoms and coenzyme Q10 administration.